Pathomechanism and Management of Stroke in COVID-19: Review of Immunopathogenesis, Coagulopathy, Endothelial Dysfunction, and Downregulation of ACE2

키워드

참고문헌 (68)

1. "WHO Timeline - COVID-19" (2020)[URL]
2. Li X, "Molecular immune pathogenesis and diagnosis of COVID-19", J Pharm Anala, 10, pp.102~108 (2020)
3. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
4. Wang D, "Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
5. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
6. Mao L, "Neurologic manifestations of hospitalized patients with Coronavirus Disease 2019 in Wuhan, China", JAMA Neurol, 77, pp.683~690 (2020)
7. Wu Y, "Nervous system involvement after infection with COVID-19 and other coronaviruses", Brain Behav Immun, 87, pp.18~22 (2020)
8. Jin H, "Consensus for prevention and management of coronavirus disease(COVID-19)for neurologists", Stroke Vasc Neurol, 5, pp.146~151 (2020)
9. Oxley TJ, "Large-vessel stroke as a presenting feature of COVID-19 in the young", N Engl J Med, 382, pp.e60~ (2020)
10. Avula A, "COVID-19 presenting as stroke", Brain Behav Immun, 87, pp.115~119 (2020)
11. Beyrouti R, "Characteristics of ischaemic stroke associated with COVID-19", J Neurol Neurosurg Psychiatry, 91, pp.889~891 (2020)
12. Lodigiani C, "Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy", Thromb Res, 191, pp.9~14 (2020)
13. Tunç A, "Coexistence of COVID-19 and acute ischemic stroke report of four cases", J Clin Neurosci, 77, pp.227~229 (2020)
14. Dogra S, "Hemorrhagic stroke and anticoagulation in COVID-19", J Stroke Cerebrovasc Dis, 29, pp.104984~ (2020)
15. Co COC, "Intravenous thrombolysis for stroke in a COVID-19 positive Filipino patient, a case report", J Clin Neurosci, 77, pp.234~236 (2020)
16. Gunasekaran K, "Stroke in a young COVID-19 patient", QJM, 113, pp.573~574 (2020)
17. Fara MG, "Macrothrombosis and stroke in patients with mild COVID-19 infection", J Thromb Haemost, 18, pp.2031~2033 (2020)
18. Al Saiegh F, "Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke", J Neurol Neurosurg Psychiatry, 91, pp.846~848 (2020)
19. Saggese CE, "COVID-19 and stroke : casual or causal role?", Cerebrovasc Dis, 49, pp.341~344 (2020)
20. Zhai P, "The impact of COVID-19 on ischemic stroke", Diagn Pathol, 15, pp.78~ (2020)
21. Goldberg MF, "Cerebrovascular disease in COVID-19", AJNR Am J Neuroradiol, 41, pp.1170~1172 (2020)
22. Yaghi S, "SARS-CoV-2 and stroke in a New York healthcare system", Stroke, 51, pp.2002~2011 (2020)
23. Su S, "Epidemiology, genetic recombination, and pathogenesis of coronaviruses", Trends Microbiol, 24, pp.490~502 (2016)
24. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
25. Rothan HA, "The epidemiology and pathogenesis of coronavirus disease(COVID-19)outbreak", J Autoimmun, 109, pp.102433~ (2020)
26. Hamming I, "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis", J Pathol, 203, pp.631~637 (2004)
27. Tay MZ, "The trinity of COVID-19 : immunity, inflammation and intervention", Nat Rev Immunol, 20, pp.363~374 (2020)
28. Xia H, "Angiotensin-converting enzyme 2 in the brain : properties and future directions", J Neurochem, 107, pp.1482~1494 (2008)
29. . Available from:https:, , doi.org, 2020.05.18.20099960, pp.2020, ~
30. Paniz-Mondolfi A, "Central nervous system involvement by Severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2)", J Med Virol, 92, pp.699~702 (2020)
31. S. Al‐Sarraj, "Invited Review: The spectrum of neuropathology in COVID‐19", Neuropathology and Applied Neurobiology, 47(1), pp.3~16 (2021), Wiley[DOI]
32. de Wit E, "SARS and MERS : recent insights into emerging coronaviruses", Nat Rev Microbiol, 14, pp.523~534 (2016)
33. Channappanavar R, "Pathogenic human coronavirus infections : causes and consequences of cytokine storm and immunopathology", Semin Immunopathol, 39, pp.529~539 (2017)
34. Xu Z, "Pathological findings of COVID-19 associated with acute respiratory distress syndrome", Lancet Respir Med, 8, pp.420~422 (2020)
35. Verdecchia P, "The pivotal link between ACE2 deficiency and SARS-CoV-2 infection", Eur J Intern Med, 76, pp.14~20 (2020)
36. Bernstein KE, "Angiotensin-converting enzyme in innate and adaptive immunity", Nat Rev Nephrol, 14, pp.325~336 (2018)
37. Mehta PK, "Angiotensin II cell signaling : physiological and pathological effects in the cardiovascular system", Am J Physiol Cell Physiol, 292, pp.C82~ (2007)
38. Pan CH, "Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation", FEBS Lett, 581, pp.526~534 (2007)
39. Hanley B, "Histopathological findings and viral tropism in UK patients with severe fatal COVID-19 : a post-mortem study", Lancet Microbe, 1, pp.e245~ (2020)
40. Jaunmuktane Z, "Microvascular injury and hypoxic damage : emerging neuropathological signatures in COVID-19", Acta Neuropathol, 140, pp.397~400 (2020)
41. Kantonen J, "Neuropathologic features of four autopsied COVID-19 patients", Brain Pathol, 30, pp.1012~1016 (2020)
42. Matschke J, "Neuropathology of patients with COVID-19 in Germany : a post-mortem case series", Lancet Neurol, 19, pp.919~929 (2020)
43. . Available from: https:, , doi.org, 2020.05.27.20114363, pp.2020, ~
44. Schurink B, "Viral presence and immunopathology in patients with lethal COVID-19 : a prospective autopsy cohort study", Lancet Microbe, 1, pp.e290~ (2020)
45. Solomon IH, "Neuropathological features of COVID-19", N Engl J Med, 383, pp.989~992 (2020)
46. Levi M, "Bidirectional relation between inflammation and coagulation", Circulation, 109, pp.2698~2704 (2004)
47. Assinger A, "Platelets in sepsis : an update on experimental models and clinical data", Front Immunol, 10, pp.1687~ (2019)
48. Cox D, "Platelets and the innate immune system : mechanisms of bacterial-induced platelet activation", J Thromb Haemost, 9, pp.1097~1107 (2011)
49. Bazaz R, "Mechanistic links between acute respiratory tract infections and acute coronary syndromes", J Infect, 66, pp.1~17 (2013)
50. Schouten M, "Inflammation, endothelium, and coagulation in sepsis", J Leukoc Biol, 83, pp.536~545 (2008)
51. Xia H, "Angiotensin-converting enzyme 2 : central regulator for cardiovascular function", Curr Hypertens Rep, 12, pp.170~175 (2010)
52. Ferrario CM, "Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7)in regulation of cardiovascular function", Am J Physiol Heart Circ Physiol, 289, pp.H2281~ (2005)
53. Khosravani H, "Protected code stroke : hyperacute stroke management during the Coronavirus Disease 2019(COVID-19)pandemic", Stroke, 51, pp.1891~1895 (2020)
54. Baracchini C, "Acute stroke management pathway during Coronavirus-19 pandemic", Neurol Sci, 41, pp.1003~1005 (2020)
55. Powers WJ, "Guidelines for the early management of patients with acute ischemic stroke : 2019 update to the 2018 Guidelines for the early management of acute ischemic stroke : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2019, pp.50, e344~
56. Smith MS, "Endovascular therapy for patients with acute ischemic stroke during the COVID-19 pandemic : a proposed algorithm", Stroke, 51, pp.1902~1909 (2020)
57. Sharma D, "Anesthetic management of endovascular treatment of acute ischemic stroke during COVID-19 pandemic : consensus statement from Society for Neuroscience in Anesthesiology & Critical Care(SNACC)", J Neurosurg Anesthesiol, 32, pp.193~201 (2020)
58. Thachil J, "ISTH interim guidance on recognition and management of coagulopathy in COVID-19", J Thromb Haemost, 18, pp.1023~1026 (2020)
59. Vivas D, "Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the working group on cardiovascular thrombosis of the Spanish Society of Cardiology", Rev Esp Cardiol, 73, pp.749~757 (2020)
60. Tang N, "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy", J Thromb Haemost, 18, pp.1094~1099 (2020)
61. Sandercock PA, "Anticoagulants for acute ischaemic stroke", Cochrane Database Syst Rev, 2015, pp.CD000024~ (2015)
62. Amin-Hanjani S, "Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice", Stroke, 32, pp.980~986 (2001)
63. Sironi L, "Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage", Arterioscler Thromb Vasc Biol, 23, pp.322~327 (2003)
64. Kawashima S, "HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats", Stroke, 34, pp.157~163 (2003)
65. Berger C, "Neuroprotection by pravastatin in acute ischemic stroke in rats", Brain Res Rev, 58, pp.48~56 (2008)
66. Yoshimura S, "Randomized controlled trial of early versus delayed statin therapy in patients with acute ischemic stroke : ASSORT trial(administration of statin on acute ischemic stroke patient)", Stroke, 48, pp.3057~3063 (2017)
67. Tan WYT, "Statin use is associated with lower disease severity in COVID-19 infection", Sci Rep, 10, pp.17458~ (2020)
68. Rossi R, "Protective role of statins in COVID 19 patients : importance of pharmacokinetic characteristics rather than intensity of action", Intern Emerg Med, 15, pp.1573~1576 (2020)

관련 논문AI추천